<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345800</url>
  </required_header>
  <id_info>
    <org_study_id>C00301</org_study_id>
    <secondary_id>2005-004417-15</secondary_id>
    <nct_id>NCT00345800</nct_id>
  </id_info>
  <brief_title>Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes</brief_title>
  <official_title>Single Center, Therapeutic Exploratory Clinical Trial to Evaluate the Safety of Sodium Oxybate (Xyrem) 500 mg/mL Oral Solution on Potential Endocrine Changes at Currently Labeled Therapeutic Dose Regimens (4.5 - 9 g/Day Divided Into Two Equal Doses) During 12 Weeks of Treatment of Cataplexy in Adult Patients With Narcolepsy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To monitor for endocrine changes in response to treatment of cataplexy with Xyrem, to focus
      on the hypothalamic pituitary axis and to confirm the safety of Xyrem on potential endocrine
      changes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The insulin-like growth factor 1 (IGF-1) measured in fasting conditions at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The insulin-like growth factor 1 (IGF-1) measured in fasting conditions after 1 month of treatment (Visit 3)</measure>
    <time_frame>After 1 month of treatment (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The insulin-like growth factor 1 (IGF-1) measured in fasting conditions after 3 months of treatment (Visit 4)</measure>
    <time_frame>After 3 months of treatment (Visit 4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The circadian rhythm of the growth hormone (GH) measured at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The circadian rhythm of the growth hormone (GH) measured at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The circadian rhythm of the growth hormone (GH) measured at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol measured at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol measured at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol measured at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adrenocorticotropic hormone (ACTH) measured in fasting conditions at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adrenocorticotropic hormone (ACTH) measured in fasting conditions at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adrenocorticotropic hormone (ACTH) measured in fasting conditions at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dehydroepiandrosterone sulfate (DHEA-S) measured in fasting conditions at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dehydroepiandrosterone sulfate (DHEA-S) measured in fasting conditions at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dehydroepiandrosterone sulfate (DHEA-S) measured in fasting conditions at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prolactin measured in fasting conditions at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prolactin measured in fasting conditions at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prolactin measured in fasting conditions at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The thyroid stimulating hormone (TSH) measured in fasting conditions at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The thyroid stimulating hormone (TSH) measured in fasting conditions at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The thyroid stimulating hormone (TSH) measured in fasting conditions at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total thyroxin (T4) measured in fasting conditions at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total thyroxin (T4) measured in fasting conditions at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total thyroxin (T4) measured in fasting conditions at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The osmolality measured in fasting conditions at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The osmolality measured in fasting conditions at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The osmolality measured in fasting conditions at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolytes (Na, K, Ca, P) measured in fasting conditions at Baseline (Visit 2)</measure>
    <time_frame>Baseline (Visit 2) - approximately 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolytes (Na, K, Ca, P) measured in fasting conditions at Visit 3</measure>
    <time_frame>Visit 3 (approximately 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolytes (Na, K, Ca, P) measured in fasting conditions at Visit 4</measure>
    <time_frame>Visit 4 (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients reporting at least one Adverse Event (AE) during the course of the study</measure>
    <time_frame>Visit 1 through the end of the study (approximately 4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patient withdrawal due to Adverse Events (AEs) during the course of the study</measure>
    <time_frame>Visit 1 through the end of the study (approximately 4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients reporting at least one Serious Adverse Event (SAE) during the course of the study</measure>
    <time_frame>Visit 1 through the end of the study (approximately 4 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Narcolepsy With Cataplexy</condition>
  <arm_group>
    <arm_group_label>Sodium Oxybate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Substance: Sodium Oxybate Pharmaceutical form: Oral Solution Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks Route of administration: Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Oxybate (Xyrem)</intervention_name>
    <description>Active Substance: Sodium Oxybate Pharmaceutical form: Oral Solution Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks Route of administration: Oral</description>
    <arm_group_label>Sodium Oxybate</arm_group_label>
    <other_name>Xyrem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Narcoleptic patients with cataplexy

        Exclusion Criteria:

          -  Subjects not diagnosed with narcolepsy with cataplexy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Li√®ge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2006</study_first_submitted>
  <study_first_submitted_qc>June 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endocrine Evaluation cataplexy</keyword>
  <keyword>sodium oxybate (xyrem)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

